Back to top
more

Adherex Technologies (FENC)

(Real Time Quote from BATS)

$4.27 USD

4.27
26,702

-0.09 (-2.06%)

Updated Nov 8, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -61.54% and 23.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -42.79% and 26.90%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -433.33% and 46.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Fortrea Holdings Inc. (FTRE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -142.86% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -26.09% and 5.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.67% and 9.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Fennec (FENC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Fennec (FENC) stock based on the movements in the options market lately.

Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 1.74% and 223.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -600% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up

by Zacks Equity Research

Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.

Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts See a 64.61% Upside in Adherex Technologies Inc. (FENC): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 64.6% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Recent Price Trend in Adherex Technologies Inc. (FENC) is Your Friend, Here's Why

by Zacks Equity Research

Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Wall Street Analysts Think Adherex Technologies Inc. (FENC) Could Surge 81%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 81% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Adherex Technologies Inc. (FENC) Could Rally 109.97%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 110% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of 36.36% and 24.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -16.67% and 17.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -9.52% and 10.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?